Literature DB >> 35584827

Acute intermittent porphyria: is oseltamivir safe in these patients?

Agustín Pijierro Amador1, Alba Suárez Cordero2, Pedro Sánchez Risco2.   

Abstract

A 40-year-old man attended the emergency room with abdominal pain and inappropriate behaviour associated with stress, and the consumption of alcohol and cannabis. Examination revealed hypertension (155/100 mmHg), tachycardia (95 beats per minute), abdominal pain and leucocytosis with neutrophilia, hyponatraemia and hypokalaemia. Urine was positive for nitrites, elevated bilirubin and cannabinoids. The patient was diagnosed with acute intermittent porphyria (AIP) and immediately treated. After initial treatment, the patient improved. However, he subsequently relapsed after initiating treatment with oseltamivir for a flu-like illness. Treatment was discontinued and the patient progressed favourably. AIP recurrence could have been mediated by oseltamivir; an association not previously described in the literature. © Royal College of Physicians 2022. All rights reserved.

Entities:  

Keywords:  acute intermittent porphyria; antivirals; oseltamivir

Mesh:

Substances:

Year:  2022        PMID: 35584827      PMCID: PMC9135073          DOI: 10.7861/clinmed.2022-0100

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   5.410


  4 in total

1.  Acute intermittent porphyria precipitated by atazanavir/ritonavir.

Authors:  Sheena Bharti; Prashant Malhotra; Bruce Hirsch
Journal:  Int J STD AIDS       Date:  2016-02-11       Impact factor: 1.359

2.  Acute intermittent porphyria and phaeochromocytoma: shared features.

Authors:  M F Stewart; J Croft; P Reed; J P New
Journal:  J Clin Pathol       Date:  2007-08       Impact factor: 3.411

3.  Acute porphyria precipitated by efavirenz.

Authors:  Christopher W Pavitt; Tommy Rampling; Ruth Byrne; Sara Tyebally; Tom Reid; Mark Nelson
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

Review 4.  Porphyrias.

Authors:  Hervé Puy; Laurent Gouya; Jean-Charles Deybach
Journal:  Lancet       Date:  2010-03-13       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.